Navigation Links
Sinobiopharma Signs Export Agreement With U.S. Pharmaceutical Supplier
Date:4/3/2009

Kingchem to Act as Agent to Find Partner to Co-Develop Company's Chinese Patented Skeletal Muscle Relaxant for North American Markets

LAS VEGAS, April 3 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) ("Sinobiopharma") (the "Company") is pleased to announce that it has signed an export agreement with Kingchem, an international marketing organization headquartered in New Jersey that specializes in custom manufacturing and sourcing of pharmaceuticals. Under the two-year agreement, Kingchem will act as an agent to find a U.S. pharmaceutical company to co-develop Sinobiopharma's Chinese patented new version of Cisatracurim besylate, a non-depolarizing pre-surgical skeletal muscle relaxant, for use in North America. Kingchem will also source buyers in North America and facilitate the export process.

Marketed under the Kutai trademark in China, the Company's formulation of Cisatracurim besylate is the world's first that can be stored at room temperature; competitors' versions must be kept at 2 to 8 degrees C. Compared to other neuromuscular blocking agents, Kutai, which is administered intravenously, is immediate in onset and longer in duration. Kutai captured an estimated 80 percent of the Chinese market within 14 months of its launch in China.

Kingchem is a well-established, respected supplier to the pharmaceutical, nutritional and fine chemical industries in the United States and Europe. With more than a decade of service, Kingchem has been recognized by its customers as a quality and reliable supplier.

"We believe this agreement is a first step in expanding the international marketing of Kutai to help generate increased sales revenues," said Sinobiopharma Vice President, Xuejun Chen.

About Kingchem LLC

Kingchem LLC acts as a third party manufacturer's agent, representing a group of first class manufacturers in China and in other parts of the world in the pharmaceutical, fine and specialty chemical, and nutritional and health food industries.

About Sinobiopharma

Sinobiopharma, Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD-LOOKING STATEMENTS

This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward-looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.


'/>"/>
SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Sinobiopharma Reports Financial Highlights for Six-Month Period Ending November 30, 2008
2. BioMaxx Systems Inc. Signs Engagement Letter With Alcofuel Technologies for Provision of an Ethanol Micro-Refinery
3. China-Biotics, Inc. Signs Intention Agreement to Supply Probiotics to Bright Dairy & Food Co., Ltd.
4. Avicena Signs Worldwide Exclusive Distribution Agreement with RITA Corporation for its Proprietary Dermaceutical Compounds
5. Monsanto Company Signs Share Subscription Agreement With Devgen
6. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
7. Shandong Zhouyuan Seed and Nursery Co., Ltd. Signs an Agreement with Linyi Company
8. Spanish Research Consortium Signs Four-Year Renewal Deal for ISI Web of Knowledge
9. Assay Designs(TM) Announces Additions to the Leadership Team
10. Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott
11. MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... 2017 , ... For the second time in three years, ... Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October 10th, ... mission is to change the trajectory of STEM education in America by dramatically ...
(Date:10/10/2017)... PA (PRWEB) , ... October 10, 2017 , ... ... year’s recipients of 13 prestigious awards honoring scientists who have ... presented in a scheduled symposium during Pittcon 2018, the world’s leading conference and ...
(Date:10/9/2017)... ... October 09, 2017 , ... ... medical journal, Epilepsia, Brain Sentinel’s SPEAC® System which uses the surface electromyography ... generalized tonic-clonic seizures (GTCS) using surface electromyography (sEMG). The prospective multicenter phase ...
(Date:10/6/2017)... , ... October 06, 2017 , ... ... a lunch discussion and webinar on INSIGhT, the first-ever adaptive clinical trial for ... Dana-Farber Cancer Institute. The event is free and open to the public, but ...
Breaking Biology Technology:
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced ... will feature emerging and evolving technology through ... Innovation Summits will run alongside the expo portion of ... sessions, panels and demonstrations focused on trending topics within ... advanced design and manufacturing event will take place June ...
(Date:4/11/2017)... -- NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" ... of independent Directors Mr. Robin D. Richards and ... furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer ... guidance and benefiting from their considerable expertise as we move ...
(Date:4/4/2017)... April 4, 2017   EyeLock LLC , a ... the United States Patent and Trademark Office (USPTO) has ... the linking of an iris image with a face ... represents the company,s 45 th issued patent. ... very timely given the multi-modal biometric capabilities that have ...
Breaking Biology News(10 mins):